Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

704

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Diabetes Mellitus
Interventions
DRUG

Pioglitazone and azilsartan

Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.

DRUG

Pioglitazone and azilsartan

Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.

DRUG

Pioglitazone

Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.

DRUG

Pioglitazone and azilsartan

Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.

DRUG

Pioglitazone and azilsartan

Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.

DRUG

Pioglitazone

Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.

Trial Locations (78)

Unknown

Birmingham

Huntsville

Sierra Vista

Sun City

Tucson

Burbank

Escondido

Irvine

La Jolla

National City

Riverside

Sacramento

San Diego

Spring Valley

Coral Gables

DeLand

Hollywood

Miami

New Port Richey

Opa-locka

Pembroke Pines

Sarasota

Vero Beach

Atlanta

Augusta

Warner Robins

Honolulu

Lihue

Chicago

Dyersburg

Overland Park

Wichita

New Orleans

Shreveport

Salisbury

Cadillac

Detroit

Livonia

Kansas City

St Louis

Las Vegas

North Las Vegas

Berlin

Blackwood

Trenton

Albany

Kingston

Charlotte

Marion

Clinton

Oklahoma City

Allentown

Altoona

Philadelphia

Scotland

Woonsocket

Greer

Arlington

Dallas

Fort Worth

Midland

North Richard Hills

San Antonio

Renton

Buenos Aires

Córdoba

Rosario-Santa Fe

Santa Fe

Ushuaia - Tierre Del Fuego

Santiago

Aguascalientes

Cuernavaca

Durango

Guadalajara

Mexico City

Puebla City

Ica

Lima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00762736 - Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter